Completes Enrollment

Related by string. * complete . completes . COMPLETES . COMPLETE . com plete . completeing : Complete Idiot Guide . READ COMPLETE ARTICLE . Complete Response Letter . Complete Response letter . Complete Count / Enrollments . ENROLLMENT . enrollments . enrollment : Enrollment Rx . Defense Enrollment Eligibility . Declining enrollment . Concurrent Enrollment . declining enrollment * *

Related by context. All words. (Click for frequent words.) 90 Completes Patient Enrollment 88 Initiates Phase II 86 Presents Positive 86 Receives Orphan Drug Designation 86 Meets Primary Endpoint 85 Initiates Clinical Trial 85 Initiates Phase III 85 Files IND 85 Initiates Enrollment 85 Enrolls First 85 Receives FDA Clearance 85 Initiates Phase 84 Phase 2b Clinical Trial 84 Presents Preclinical Data 84 Clinical Trial Results 84 Initiates Clinical 84 Announces Initiation 83 FDA Clears 83 Drug Candidate 83 Patient Enrollment 83 Commences Phase 83 Submits NDA 83 Announces FDA Clearance 83 Begins Dosing 83 Phase IIb Trial 83 Phase III Trial 83 Phase III Clinical Trial 82 Study Evaluating 82 Announce License Agreement 82 Present Preclinical Data 82 Receives Approvable Letter 82 Receives Milestone Payment 82 Phase 2b Trial 82 Demonstrates Significant 82 Pivotal Phase III 82 Collaborators Present 82 FDA Approves 81 Phase IIb Clinical Trial 81 Patients Enrolled 81 Successfully Completes Phase 81 Demonstrates Positive 81 Presents Preclinical 81 Clinical Trial Evaluating 81 Initiates Clinical Trials 81 Novel Oral 81 Initiate Phase III 81 Pivotal Study 80 Submits Biologics License Application 80 FDA Accepts 80 Preclinical Data 80 Pivotal Phase 80 First Patient Enrolled 80 Improves Survival 80 Initiate Phase 80 Granted Orphan Drug 80 PRN FDA Approves 80 Pivotal Trial 80 Announces Publication 80 Trial Evaluating 80 Patients Treated With 80 Reveals Positive 80 Gets FDA Clearance 79 Achieves Primary Endpoint 79 Announces Positive 79 Investigational Compound 79 Phase 2a Clinical Trial 79 FDA Approvals 79 Initiates Phase 2b 79 Completes Dosing 79 Mylan Receives Approval 79 Receives Orphan Drug 79 Initiates Dosing 79 Announces Presentation 79 Patients Treated 78 Single Dose 78 Drug Fails 78 Licenses Novel 78 Combination REOLYSIN R 78 Reports Preclinical Data 78 Reports Positive 78 Earns Milestone Payment 78 Prolongs Survival 78 Announce Initiation 78 Pooled Analysis 78 Phase 2a Trial 78 Study Demonstrates 78 Therapeutic Competitors Companies 78 FDA Okays 78 II Clinical Trial 78 Previously Treated 78 Submits IND 78 Spectrum Pharmaceuticals Announces 78 Phase III Pivotal 78 Shows Promising 78 JAK2 Inhibitor 77 Phase IIa Clinical Trial 77 NDA Submission 77 Improves Outcomes 77 Oral Calcitonin 77 Presents Positive Preclinical 77 Announces Tentative Approval 77 Announces Successful Completion 77 Dose Ranging Study 77 First Patient Dosed 77 Announces Poster Presentations 77 Commence Phase 77 Submits Response 77 Pivotal Clinical Trial 77 Adjunctive Therapy 77 Receives Patent 77 Patent Issued 77 Completes Patient Enrolment 77 First Patient Treated 77 Significantly Reduces 77 Files Investigational 77 Vaccine Adjuvant 77 IND Filing 77 Receives Fast Track 77 Well Tolerated 77 Randomized Phase 77 Study Showed 76 Shows Promise 76 Combination Treatment 76 Lupus Drug 76 Announce Collaboration Agreement 76 Achieves Milestone 76 Oral Fingolimod 76 Advanced Melanoma 76 Announce Merger Agreement 76 Phase 1b Clinical Trial 76 Announces License Agreement 76 Develop Novel 76 Receives SFDA Approval 76 Chronic Hepatitis C 76 Announces Licensing Agreement 76 Adjuvant Treatment 76 Severe Sepsis 76 Randomized Double Blind 76 Announces Dosing 76 Sign Licensing Agreement 76 Osteoporosis Drug 76 IND Application 76 Drug Shows Promise 76 Sign License Agreement 76 pralatrexate injection folate analogue 76 dependent kinase inhibitor 76 Files Patent Application 76 Patent Covering 76 Obtains FDA 76 Tezampanel 76 Antitumor Activity 76 Launches Generic Version 76 Complicated Skin 76 Significantly Improves 76 Controlled Study 76 Investigational Treatment 76 Receive Milestone Payment 76 Taro Receives 76 Investigational Oral 76 Initiate Clinical Trial 76 Preclinical Study 75 Cholesterol Lowering Drug 75 Hsp# Inhibitor 75 Arthritis Drug 75 Double Blind Placebo 75 Milestone Payment 75 Reduces Risk 75 Q3 Loss Widens 75 Provides Update Regarding 75 Submits Application 75 Demonstrates Sustained 75 Hypertensive Patients 75 Generic Version 75 Migraine Drug 75 Phase III Trials 75 Protease Inhibitor 75 Metastatic Melanoma 75 Receives Positive Opinion 75 Patients Undergoing 75 Receives Positive 75 Clinical Study Shows 75 FDA APPROVES 75 JAK Inhibitor 75 BioSante Pharmaceuticals Announces 75 Receives NASDAQ 75 Awarded Patent 75 Biogen Genentech 75 Receives Tentative Approval 75 Topline Results 75 Announce Licensing Agreement 75 Gout Drug 75 Expanded Indication 75 Submits Supplemental 75 Inc. Nasdaq OXGN 74 Anti Tumor Activity 74 Sirolimus Eluting Stent 74 Xcytrin R 74 Teva Provides Update 74 Newly Diagnosed Multiple Myeloma 74 Q2 Loss Narrows 74 Signs License Agreement 74 Begins Shipment 74 Q4 Loss Widens 74 Long Term Efficacy 74 Receives Favorable 74 Effectively Treats 74 Announces Favorable 74 Prostate Cancer Vaccine 74 Receives Complete Response 74 Sinks Lower 74 Therapeutic Competitors companiesandmarkets.com adEgemonye 74 Demonstrates Potential 74 Immunomedics Announces 74 Heart Failure Patients 74 Kinase Inhibitor 74 Cites Positive 74 Announces Issuance 74 R roscovitine CDK cyclin 74 Confirmatory Phase 74 Phase 2b Study 74 Agonist MABA program 74 Jumps Higher 74 Ovitrelle R Serostim 74 Clinical Study 74 Proves Effective 74 Announces Commencement 74 R lenalidomide 74 Controlled Trial 74 Metastatic Colorectal Cancer 74 Q4 Loss Narrows 74 Reacquires 74 Nasdaq XTLB 74 Epilepsy Drug 74 Humanized Anti 74 Elderly Patients 74 Pivotal Trials 74 Pharmaceuticals Initiates 74 Randomized Double blind 74 TO AVOID PREGNANCY WHILE 74 Successfully Treats 74 HCV Protease Inhibitor 74 Receives CE Marking 74 Transdermal Patch 74 Appears Safe 74 Novel Antibiotic 73 Lung Cancer Drug 73 Obtains Approval 73 Q2 Loss Widens 73 R MSCRAMM 73 Q1 Loss Narrows 73 Patients Suffering 73 Treatment Naïve 73 Cypher Sirolimus 73 Shows Promise Against 73 Slows Progression 73 Vitrasert R 73 Monotherapy 73 markets COLAZAL 73 Successful Completion 73 Brentuximab Vedotin SGN 73 Expand Collaboration 73 Signs Licensing Agreement 73 Patient Treated 73 Demonstrates Efficacy 73 Polymerase Inhibitor 73 TRANSDUR ® 73 Successfully Treated 73 Previously Untreated 73 Increases Risk 73 Board Authorizes 73 Eluting Stent 73 Slow Progression 73 Receives Regulatory 73 Survival Benefit 73 Treatment Experienced 73 Randomized Clinical Trial 73 Announce Collaboration 73 Successfully Completes 73 Postmenopausal Women 73 Collaborators Publish 73 Receives Notice 73 Plaque Psoriasis 73 Is Well Tolerated 73 Amends Agreement 73 Relapsing Multiple Sclerosis 73 Systemic Delivery 73 Personalized Immunotherapy 73 Q3 Loss Narrows 73 Receives CE 73 vapreotide acetate 73 Elagolix 73 Namenda Memantine HCl 73 Demonstrated Significant 73 5q MDS 73 By JENNIFER LEARN 73 Inc Therapeutic Competitors 73 Demonstrates Potent 73 SABER ™ 73 developing Bicifadine serotonin 73 ORLive Presents 73 Significantly Increases 73 Regains Compliance 73 Shows Efficacy 73 Files Shelf Registration Statement 73 Cholesterol Drug 73 Subgroup Analysis 73 Prostate Cancer Patients 73 Proven Effective 73 Announces Termination 73 TRANSDUR ™ 73 Taglich Brothers Initiates Coverage 73 Mg Usa 73 Announce Definitive Agreement 73 Secures Financing 73 Announce Receipt 73 Announces Immediate Availability 73 Anti Tumor 73 Hormone Refractory Prostate Cancer 73 Telaprevir VX 73 Pharmacyclics Announces 73 Pharmacokinetic Study 73 Commences Phase III 73 Adjuvant Chemotherapy 73 Phase 2a Study 73 Phase Ib Clinical Trial 72 Tyrosine Kinase Inhibitor 72 Randomized Study 72 IG HCR ;) CO 72 TM Aganocide 72 Announces Completion 72 Flamel Technologies Announces 72 Q1 Loss Widens 72 Randomized Double Blind Placebo 72 Recombinant Human 72 AUDIO PROVIDED BY 72 Announces Dismissal 72 Pharma Merck Serono 72 Prospective Randomized 72 Relapsed Refractory 72 Lowers Risk 72 Telik logo TELINTRA 72 Improve Survival 72 Commercializes 72 Chronic Hepatitis B 72 BIOTECHNOLOGY SOURCE 72 Announces Stockholder Approval 72 Investigational Drug 72 Receives Conditional 72 Vicriviroc 72 Molecular Diagnostic Test 72 Anticancer Activity 72 Begins Clinical Trial 72 Significantly Reduced 72 Nicotine Vaccine 72 Rheumatoid Arthritis Drug 72 Confirms Efficacy 72 VIVUS Announces 72 Treatment Reduces 72 Low Dose 72 R Saizen R 72 diarrhea fatigue asthenia 72 Clinical Evaluation 72 novel orally inhaled 72 Settle Patent Litigation 72 Receives Notification 72 includes Dideco CarboMedics 72 Cutaneous T 72 CHEAP ONLINE PHARMACY LOW 72 Lung Cancer Trial 72 Successfully Completed 72 Successfully Completes Tender Offer 72 RNAi Therapeutic 72 Exercises Option 72 Refractory Hodgkin Lymphoma 72 Initiates Voluntary Recall 72 Secondary Hyperparathyroidism 72 oral nucleoside analogue 72 Dose Ranging 72 IN PATIENTS WITH 72 Updates Status 72 Receives Clearance 72 Stent Implantation 72 Sangamo BioSciences Announces 72 Clinical Efficacy 72 Psoriasis Drug 72 Introduces Next Generation 72 Vascular Disrupting Agent 72 Receives Favorable Ruling 72 Randomized Phase II 72 Regains NASDAQ 72 Randomized Trials 72 Generic Versions 72 Supplemental Biologics License Application 72 Crofelemer budesonide foam 72 Renal Cell Carcinoma 72 Resistant Hypertension 72 Versus Placebo 72 Drug Coated Stent 72 Phase III Clinical Trials 72 Provides Guidance 72 Combination Therapy 72 Acquires Exclusive 72 Nasdaq SMTS develops manufactures 72 Shows Statistically Significant 72 Completes Successful 72 Signs Agreements 72 Awarded Patents 72 Issued Patent 72 Novartis Novo Nordisk 72 HDAC Inhibitor 72 Dose Escalation 72 Patients Receiving 72 Hematology Molecular Pathology 72 MKC# 72 Hemodialysis Patients 72 Patient Enrolment 72 Nasdaq VNDA 72 NOTE POSIDUR ™ 72 Blood Pressure Drug 71 platform HDL Mimetic 71 Therapy Improves 71 Advanced Prostate Cancer 71 PPD Declares 71 Node Positive 71 Infected Patients 71 Pafuramidine 71 Bone Metastases 71 TKB# 71 Metabolic Efficiency 71 TM Drug Eluting 71 VentiRx Pharmaceuticals 71 Treating Chronic 71 phenyl salicylate methylene blue 71 Acute Attacks 71 Colaris Colaris AP 71 Rheumatoid Arthritis Patients 71 Announces Preliminary 71 Inhaled Insulin 71 Luveris R Ovidrel R 71 Introduces Novel 71 Drug Combo 71 Randomized Controlled 71 Diabetic Patients 71 Study Validates 71 Data Suggest 71 Augment TM 71 Disease Modifying 71 particularly SANCTURA XR 71 Unfractionated Heparin 71 Placebo Controlled Trial 71 Non Invasive Treatment 71 Schizophrenia Drug 71 Introduces Revolutionary 71 Osteoporosis Treatment 71 Net Loss Widens 71 Announces Effective Date 71 Explore Strategic Alternatives 71 Voluntarily Withdraw 71 Downtrend Spotted 71 Oral Laquinimod 71 MKC# MT 71 Fungal Infections 71 Diabetic Foot Ulcer 71 Study Shows Benefits 71 Plus Ribavirin 71 sapropterin dihydrochloride 71 Extends Collaboration 71 Monoclonal Antibody 71 Obtains License 71 Inhibits 71 Therapeutic Antibody 71 Relapsed Multiple Myeloma 71 HER2 Positive 71 REG1 Anticoagulation System 71 FDA Panel Recommends 71 Milestone Achieved 71 Awarded Qualifying Therapeutic 71 Reminds Shareholders 71 Settles Litigation 71 Regains Compliance With 71 Study Indicates 71 Systemic Sclerosis 71 Discontinues 71 FOLOTYN ® 71 Net Loss Narrows 71 THERAPEUTICS 71 Announces Filing 71 Completes Tender Offer 71 Enrolling Patients 71 SHAREHOLDERS ARE STRONGLY ADVISED 71 Receives Approval 71 Updates Guidance 71 initiated Phase Ib 71 Develops Novel 71 release capsules FENTORA 71 Advanced Renal Cell 71 Fast Track Status 71 Novel Inhibitor 71 Efficacy Results 71 markets HP Acthar 71 Study Confirms 71 Placebo Controlled 71 Bullish Technical Alert 71 MONSTERSTOX.COM Monsterstox.com 71 FDA Approves Drug 71 Seliciclib CYC# 71 Announces Receipt 71 Obtains Exclusive License 71 Investigational Agent 71 Announces Adjournment 71 Phase IIa Trial 71 CysDisplay R 71 R famotidine 71 FDA Clearance 71 evaluating picoplatin 71 Poniard Pharmaceuticals Announces 71 developing ACAPODENE 71 Improved Survival 71 Orally Active 71 Cell Transplants 71 CybeRelease Decliners 71 Genentech GlaxoSmithKline 71 Parathyroid Hormone 71 Aztreonam Lysine 71 Inc. ProMetic www.prometic.com 71 Small Molecule 71 Reports Receipt 71 Significantly Improved 71 MKC# MKC# PP 71 Prophylactic Treatment 71 Vertex Pharmaceuticals Announces 71 estrogen receptor beta agonist 71 Second Pivotal Phase 71 Regains Full 71 Welcomes Analyst Initiation 71 Veronate R 71 Study Shows Promise 71 CHEAP ONLINE PHARMACY BEST 71 lead molecular radiotherapeutic 71 Jointly Announce 71 NICE Recommends 71 Announce Availability 71 Commercialize 71 Subsidiary Enters 71 WRX STi +# mins 71 Oral Formulation 71 Announces Cancellation 71 Kidney Transplant Patients 71 Myeloma Patients 71 AAG geldanamycin analog 71 Patient Dosing 71 Extends Tender Offer 71 Nuvelo Announces 71 Secures Additional 71 Metastatic Prostate Cancer 71 Novel Treatments 71 Drug Eluting 71 Milestone Payments 71 Identifies Potential 71 Completes Merger With 71 Bullish Average Crossover 71 Genentech Wyeth Pharmaceuticals 71 Medoxomil 71 Overactive Bladder 71 Efficacy Trial 71 COMUNICADO DE 71 Alvine Pharmaceuticals 71 Pediatric Patients 71 Treatment Resistant 71 Blood Thinner 71 ELADUR ™ 71 Begins Shipping 71 pan histone deacetylase 71 Antibody Drug Conjugate 71 Platelet Inhibition 71 Crit Rev 71 Multiple Ascending Dose 71 AVI BioPharma Announces 71 Completes Merger 71 Drug Eluting Stent 71 INDUSTRY ASSESSMENTS 71 Treatment Naive Patients 71 Predict Risk 71 Phospholipase A2 71 J Am Coll 71 Consummates 71 Reduces Pain 71 Recommends Approval 71 Statin Therapy 71 Demonstrate Significant 71 Announces Signing 71 Proves Successful 71 Submits Investigational 71 Upcoming Deadline 71 Chemotherapy Induced Anemia 71 Atypical Hemolytic Uremic Syndrome 71 MEK Inhibitor 70 Attains 70 BY RYAN ERNST 70 PEGylated Fab fragment 70 Proc Am Soc 70 Regenerative Cells 70 Novel Compounds 70 please visit http:/www.vandapharma.com 70 Lung Cancers 70 benzoic acid hyoscyamine sulfate 70 product platforms AZX# 70 Merck OSI Pharmaceuticals 70 Evaluate Strategic Alternatives 70 Less Invasive 70 Orthop Surg 70 Announces Webcast 70 Nasdaq PGNX 70 markets XIFAXAN ® 70 Dose Finding 70 Adjuvant Therapy 70 CONTINUES LOWER 70 ATRA IV 70 Breast Cancer Recurrence 70 Roche Boniva 70 acetonide FA 70 Early Relapsing Multiple 70 ODT metoclopramide HCl PEPCID 70 Bush Embraces Pause 70 Sirolimus Eluting 70 Invites Investors 70 XL# anticancer compounds 70 ELADUR TM 70 sanofi aventis Bayer Schering 70 Shareholders Approve Acquisition 70 TriCo Bancshares Announces 70 Inflammatory Arthritis 70 Signs Option Agreement 70 Finalizes Acquisition 70 Reduces Mortality 70 Anticancer Drug 70 DAY PATTERN FOR 70 Therapeutic Competitors Report 70 Files Patent 70 Expands Portfolio 70 COMPLETES ACQUISITION OF 70 evaluating mipomersen 70 Drug Prevents 70 Bare Metal Stents 70 Abstract Accepted 70 WorldHeart Announces 70 Acquire Assets 70 Hematological Malignancies 70 Wafer polifeprosan 70 methylnaltrexone bromide 70 Receptor Antagonist 70 Announces Successful 70 RNAi Therapeutics 70 Options Trader Alert 70 Demonstrates Statistically Significant 70 Enters Into License Agreement 70 Osteoporosis Drugs 70 topical gel formulation 70 Nasdaq MNKD focuses 70 Postmenopausal Osteoporosis 70 Inks Licensing Deal 70 dihydrochloride Tablets 70 Completes Initial 70 Knee Osteoarthritis 70 PROVENGE ® 70 Pulmonary Arterial Hypertension 70 Desvenlafaxine Succinate 70 FDA Approval 70 Preclinical Models 70 Diabetic Neuropathy 70 Beneficial Effects 70 PRESENTED AT 70 Carboplatin Paclitaxel 70 Univest Corporation Declares 70 PRN4 70 Posts Wider Loss 70 BIOLASE Announces 70 lexidronam injection 70 Bosutinib 70 Provides Updates 70 Biomarker Study 70 Am J Obstet 70 Lupus Nephritis 70 Mutually Agree 70 Provides Shareholder 70 PRICE GREAT DISCOUNT FREE 70 Moving Average Crossover Alert 70 Enters Agreement 70 Announce Completion 70 Signs Merger Agreement 70 Treated Patients 70 Nasdaq HALO 70 Myriad logo BRACAnalysis 70 Vitrasert ® 70 Glatiramer Acetate 70 Expands Scientific Advisory 70 Levels Linked 70 brand ciclesonide HFA 70 Stent Restenosis 70 Randomized Clinical Trials 70 Announces Definitive Agreement 70 Boehringer Ingelheim MedImmune 70 Testosterone Gel 70 investigational oral inhibitor 70 Testosterone MDTS R 70 Lanthanum Carbonate 70 Vascular Grafts 70 Patient Accrual 70 Holds Promise 70 Novel Compound 70 COMUNICADO 70 Aloxi ® 70 Hormone Receptor Positive 70 Launches Next Generation 70 J Am Acad 70 Enters Into Licensing Agreement 70 candidates Azedra TM 70 INSPIRE Trial Phase III 70 Multicenter Phase 70 Technicals Showing Bullish 70 Receptor Agonist 70 Bullish Engulfing Pattern 70 Milestone Payment From 70 Renal Impairment 70 Positive Results 70 ALN HPN 70 visit http:/www.mannkindcorp.com 70 STERIS Corporation Announces 70 Regenerative Cell 70 interferon beta 1a infertility 70 Antiviral Activity 70 Carotid Stenting 70 Terminate Merger Agreement 70 catheter occlusion 70 Pegloticase 70 Bearish Speculation 70 Announces Underwriters Exercise 70 Romidepsin 70 Pending Acquisition 70 Test Detects 70 FDA Warns 70 Reports Significantly Improved 70 Bearish Average Crossover 70 Bifunctional Muscarinic Antagonist Beta2 70 Technicals Showing Bearish 70 Updates Shareholders 70 Paclitaxel Eluting 70 READ THE DEFINITIVE 70 Soft Tissue Sarcoma 70 Acquire Controlling Interest 70 Zorbtive TM 70 Rotavirus Vaccine 70 Clinical Outcome 70 PLEASE READ THE FOLLOWING 70 Initiated Phase 70 Statistically Significant 70 Puts Purchased 70 Advanced Colorectal Cancer 70 Staphylococcus aureus Immune Globulin 70 oncolytic virus therapies 70 Initiate Phase II 70 Corp. AMEX CVM 70 Acute Myocardial Infarction 70 Novartis Organon 70 Shareholders Approve Merger 70 Treatment Shows Promise 70 ® DS methenamine 70 Settle Patent Dispute 70 Mouse Model 70 undergoing elective percutaneous 70 Restructures Operations 70 Biopharmaceuticals AG 70 Calls Purchased 70 AnaSpec Introduces 70 PHASE III 70 Strengthens Balance Sheet 70 Webcast Presentations 70 Pruvel TM 70 Improves Quality 70 Patents Covering 70 Shareholders Approve Merger Agreement 70 的 中 70 Left Ventricular Hypertrophy 69 Further Validates 69 Drug Eluting Coronary Stent 69 Cerebril TM 69 Diabetic Nephropathy 69 DARA logo 69 Sagent Pharmaceuticals Announces 69 Genentech sanofi aventis 69 Benign Prostatic Hyperplasia 69 AS CALL VOLUME 69 Oral Cladribine 69 Peginterferon Alfa 2a 69 Therapeutic Vaccine 69 Clinical Trial Data 69 By JAMAAL ABDUL 69 please visit http:/www.atherogenics.com 69 Mg Uk 69 Inhalation Aerosol 69 pentadentate logo R 69 Inc. www.micromet inc.com 69 IIa Clinical Trial 69 submitted supplemental Biologics 69 Increased Risk 69 Acute Ischemic Stroke 69 Announces Availability 69 Uptrend Spotted 69 Novel Mechanism 69 Naive Patients 69 Successfully Concludes 69 Releases Next Generation 69 Strengthens Position 69 Closes Sale 69 Unanimously Recommends Approval 69 Successfully Complete 69 Underwritten Public 69 Announce Early Termination 69 VIVITROL ® 69 Gene Mutation 69 Topical Treatment 69 Nasdaq AVNC 69 albiglutide 69 drug pipeline TAFA# 69 rilonacept Injection 69 Potent Antiviral Activity 69 Announce Expiration 69 Announce Commencement 69 Cardiovascular Events 69 Frozen Shoulder syndrome Adhesive 69 non nucleoside inhibitor 69 DIURIL R 69 Derma Sciences Announces 69 Autologous Stem Cell Transplantation 69 Helps Predict 69 bone marrow reticulin deposition 69 Exherin 69 dasatinib Sprycel ® 69 Achieves Positive 69 sarcoma melanoma 69 myocardial infarction ventricular fibrillation 69 FEMALES SHOULD BE ADVISED 69 Embolic Protection 69 THE COMPANY CONTAIN CERTAIN 69 CALL VOLUME UP 69 Announce Agreement 69 Introduces Enhanced 69 Poster Presentations 69 Canaccord Genuity Maintains Hold 69 Strengthens Its 69 CONFERENCE CALLS SOURCE 69 Solution XOPENEX HFA 69 evaluating bafetinib 69 essential thrombocythemia ET 69 Vascular Inflammation 69 Testosterone MDTS ® 69 OTCBB FCSC 69 SPRYCEL ® 69 Bristol Myers Squibb sanofi 69 Complete Merger 69 Vaccine Protects Against 69 LifeVantage Announces 69 AFFECT MICROSEMI 'S 69 Randomized Phase III 69 Inc. OTCBB ECTE 69 Wins Patent Infringement 69 TELINTRA R 69 Intravitreal 69 Issues Guidance 69 Telik Announces 69 Phase III Pivotal Trial 69 Enters Into Agreement 69 Stockholders Approve Merger 69 Positive Opinion 69 Completes Previously Announced 69 COLAZAL ® 69 Cardiovascular Prosthetic Devices 69 Restructures Debt 69 Sapacitabine 69 Tumor Growth 69 Anticancer Agent 69 Begin Clinical Trials 69 Closes Merger 69 Interferon Alpha 69 Underwriters Exercise 69 Effective Than 69 Bullish Speculation 69 oral prodrug 69 balsalazide disodium Capsules 69 Achieves Unprecedented 69 Bristol Myers Squibb Celgene 69 Options Activity 69 Nasdaq ZGEN 69 Anti Inflammatory 69 Antigen Specific 69 REMINDER ORLive Presents 69 researches develops licenses 69 PET FROM 69 mGluR5 negative 69 RISKS AND UNCERTAINTIES THAT 69 Files Registration Statement 69 Receives Conditional Approval 69 BELIEFS PLANS EXPECTATIONS OR 69 Provide Comprehensive 69 Myelofibrosis 69 Previously Announced 69 Intravenous Formulation 69 IS BEING MADE ONLY 69 ABLYNX 69 LENALIDOMIDE 69 Announce Settlement 69 Gene Linked 69 BCG refractory carcinoma 69 CD# CEA 69 BAG# BAG# BAG# BAG# 69 ST Elevation Myocardial 69 RISKS UNCERTAINTIES AND ASSUMPTIONS 69 TRACON Pharmaceuticals 69 DETECTS POSSIBLE BEARISH INSIDE 69 SIDE EFFECTS CHEAP ONLINE 69 NicVAX TM 69 NASDAQ ADLR 69 topical antifungal product 69 CAREFULLY READ THESE MATERIALS 69 Subsidiary Receives 69 arsenic trioxide injection GABITRIL 69 Nasdaq EPCT 69 Results Confirm 69 Advanced Pancreatic Cancer 69 Replacement Therapy 69 R memantine HCl 69 EBAY OR OTHER 69 hypertrichosis occurred 69 SMARTREND DETECTS CONTINUED SELLING 69 By Phillip Ramati 69 Multicenter Randomized 69 Boxed Warnings 69 Bearish Dark 69 ERBITUX cetuximab 69 Prodrug 69 includes TOLAMBA TM 69 REDUCED DEMAND FOR 69 Introduces Breakthrough 69 Announces Enhancements 69 Implantable Device 69 INDICATED LOWER 69 SMARTREND 'S OPTION SCANNER 69 PRODUCT SOURCE 69 Unveils Latest 69 Inhaled Corticosteroids 69 Canaccord Genuity Reiterates Buy 69 arsenic trioxide injection 69 Reconfirms 69 Board Unanimously Rejects 69 Study Proves 69 hypoxia activated prodrug 69 Chronic Myeloid Leukemia 69 transthyretin mediated amyloidosis ATTR 69 Disease Progression 69 Hydrochlorothiazide Tablets 69 OTCBB IMUC 69 Sandostatin R 69 induced macular edema 69 topically applied SEPA 69 Vitro Activity 69 CYT# potent vascular disrupting 69 Guidelines Issued 69 REPRONEX R menotropins 69 Tumor Targeting 69 AND UNKNOWN COULD CAUSE 69 erlotinib Tarceva R 69 Breast Cancer Patients 69 Non Invasive 69 myelodysplastic myeloproliferative diseases 69 Inflammatory Disease 69 myocardial infarction hypersensitivity 69 lintuzumab SGN 69 NASDAQ MNKD focuses 69 R bisoprolol Euthyrox 69 Lowers Guidance 69 PRN8 69 Anticancer Compound 69 Pomerantz Law Firm 69 Shown Effective 69 Announces Additions 69 Announces Divestiture 69 'S PRESENT BELIEFS AND 69 Revises FY# Outlook 69 Interesting Options Volume 69 BIDDING AT THIS AUCTION 69 Gel repository corticotropin injection 69 Announces Postponement 69 TNF Blockers 69 Upcoming Conferences 69 Meta Analysis 69 Chemotherapeutic Agents 69 Using Dip Pen 69 Endovascular Treatment 69 Researchers Identify

Back to home page